Table 2.
Apical lesion patient characteristics
| Indiana University | Karolinska University | Total | |
|---|---|---|---|
| Number of patients | 37 | 52 | 89 |
| Gender | |||
| Male | 21 | 23 | 44 |
| Female | 16 | 29 | 45 |
| Age at treatment, median (range) | 73 (57–81) | 72 (35–88) | |
| Number of tumors | 37 | 56 | 93 |
| Primary lung cancer (NSCLC) | 37 | 30a | 67 |
| Metastases | 0 | 22 | 22 |
| Tumors | |||
| Right | 21 | 28 | 49 |
| Left | 16 | 28 | 44 |
| Volume cc, median (range) | GTV 13 (1–113) | CTV 9.1 (0.10–74.5) | |
| Follow-up months, median (range) | 13 (1–71) | 30 (6.1–72.2) | |
| Total treatment dose (Gy), median (range) | 57 (30–72) |
Median 45 Gy in 3 fx BED10 Range: 95–138 Gy |
|
| Median dose per fraction (Gy) (range) | 19 (10–24) | 15 (6–17) | |
| Median number of fractions (range) | 3 (3–4) | 3 (3–10) | |
| Number of patients with brachial plexopathy | |||
| Total | 7 | 7 | 14 |
| Grade 2 | 4 | 3 | 7 |
| Grade 3 | 2 | 4 | 6 |
| Grade 4 | 1 | 0 | 1 |
| Brachial plexopathy development in months post-SBRT, median (range) | 7 (6–23) | 5.8 (0.7–13) | |
NSCLC non-small cell lung cancer, GTV gross tumor volume, CTV clinical tumor volume, fx fractions; BED10 biological effective dose with α/β = 10 Gy
aOne patient with metastasis later on